

Comparison of Brixadi vs Sublocade

Feature	Brixadi	Sublocade
Dosing Options	<ul style="list-style-type: none"> • 7 dose options (weekly & monthly) 	<ul style="list-style-type: none"> • 2 dose options (monthly only)
<ul style="list-style-type: none"> • Formulations 	<ul style="list-style-type: none"> • Weekly and monthly 	<ul style="list-style-type: none"> • Monthly only (can be given every other month)
<ul style="list-style-type: none"> • Induction Timing 	<ul style="list-style-type: none"> • Can be started earlier in withdrawal, useful in acute settings 	<ul style="list-style-type: none"> • Requires moderate withdrawal symptoms and at least one sublingual dose before initiation
<ul style="list-style-type: none"> • Injection Volume 	<ul style="list-style-type: none"> • Smaller (0.16–0.64 mL); less painful 	<ul style="list-style-type: none"> • Larger (0.5–1.5 mL)
<ul style="list-style-type: none"> • Needle Size 	<ul style="list-style-type: none"> • Thinner 23-gauge needle 	<ul style="list-style-type: none"> • Thicker 19-gauge needle
<ul style="list-style-type: none"> • Injection Experience 	<ul style="list-style-type: none"> • Faster injection (a few seconds); less painful 	<ul style="list-style-type: none"> • Slower injection (30–60 seconds); more discomfort
<ul style="list-style-type: none"> • Patient Preference 	<ul style="list-style-type: none"> • Higher satisfaction in some studies; less injection site pain 	<ul style="list-style-type: none"> • Lower preference among patients with experience of both
<ul style="list-style-type: none"> • Flexibility for Monitoring 	<ul style="list-style-type: none"> • Weekly dosing allows closer follow-up for high-need patients 	<ul style="list-style-type: none"> • Monthly/every-other-month better for stable patients
<ul style="list-style-type: none"> • Induction in Acute Settings 	<ul style="list-style-type: none"> • Suitable due to low risk of precipitated withdrawal 	<ul style="list-style-type: none"> • Less ideal for rapid induction

From the Clinical Update:
“Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder”
 By Crystal Obiozor, MD and Noah Capurso, MD, MHS
The Carlat Addiction Treatment Report, Volume 13, Number 5&6, July/August/September 2025
www.carlataddictiontreatment.com